Netherlands-based biotech Citryll has dosed the first subject in the randomised Phase IIa trial, Citydream, assessing its monoclonal antibody CIT-013, intended for individuals with moderately active rheumatoid arthritis (RA), a chronic autoimmune disorder.
The multi-centre, double-blind, placebo-controlled trial is being carried out across various European sites.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It aims to evaluate the safety, tolerability and efficacy of the antibody in those with moderately active RA.
The study plans to recruit 88 subjects who will participate in a treatment period for six weeks. An open-label extension period will follow for further evaluation of the treatment’s efficacy and safety.
To bolster the trial’s progress, Citryll has assembled a Clinical Advisory Board for RA, consisting of experts in the domain.
This board is tasked with offering scientific and strategic advice during CIT-013’s clinical development for RA and potentially other autoimmune conditions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRA is marked by joint inflammation, leading to symptoms such as stiffness, swelling, and pain. These symptoms often result in reduced mobility and joint damage over time.
This latest trial follows Citryll’s first-in-human Phase I trial completion, which involved repeated dosing in RA subjects, and comes after an €85m Series B fundraising effort.
Additionally, the company noted that it is preparing for another Phase IIa study targeting hidradenitis suppurativa (HS), set to begin later in the year.
Citryll’s chief medical officer Maarten Kraan stated: “The dosing of the first patient in our Phase IIa trial marks a significant milestone in Citryll’s mission to transform the treatment landscape for patients suffering from immune-mediated inflammatory conditions such as rheumatoid arthritis.
“Citydream represents an important step in validating the potential of CIT-013 in RA, and we remain deeply committed to bringing this promising therapy to patients.”
CIT-013 has a dual mechanism of action that not only enhances the clearance of existing neutrophil extracellular traps (NETs) but also inhibits their formation.
